Integrated Media Technology Limited IMTE 深 沪
等待开盘 11-07 09:30:00 美东时间
0.8682
-0.007
-0.78%
华盛通- 最 高0.8849
- 今 开0.8301
- 成交量 5.90万股
- 最 低 0.7905
- 昨 收 0.875
- 总市值 297.91万
- 52周最高 3.17
- 市盈率 静 --
- 换手率 1.72%
- 52周最低 0.5101
- 委 比 -75.44%
- 总股本 343.14万
- 历史最高 440.00
- 量 比 0.79
- 振 幅 10.79%
- 历史最低 0.10
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Integrated Media Technology Limited Receives Nasdaq Delisting Determination Letter For Failing To File Its 2024 Form 20-F By Required Deadline And Did Not Regain Compliance
On October 30, 2025, Integrated Media Technology Limited (the "Company") received a delisting determination letter (the "Determination Letter") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock
10-31 20:23
10 Information Technology Stocks Moving In Monday's Pre-Market Session
Gainers Pixelworks (NASDAQ:PXLW) shares rose 28.6% to $16.51 during Monday's p...
10-13 20:09
12 Information Technology Stocks Moving In Wednesday's After-Market Session
Gainers Next Technology Holding (NASDAQ:NXTT) shares increased by 15.0% to $0....
09-04 05:06
Why EpicQuest Education Shares Are Trading Higher By Over 81%; Here Are 20 Stocks Moving Premarket
Shares of EpicQuest Education Group International Ltd (NASDAQ:EEIQ) rose sharpl...
08-22 20:01
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Immutep Limited has received positive feedback from the US FDA regarding its first-in-class MHC Class II agonist, eftilagimod alfa (efti), for the treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with PD-L1 expression below 1 (CPS <1). The FDA supports further clinical development of efti in combination with KEYTRUDA, acknowledging its potential to address high unmet needs in this patient population. Pos...
08-05 12:00
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Limited, a late-stage immunotherapy company, announces that three abstracts for clinical trials evaluating its MHC Class II agonist eftilagimod alfa (efti) have been accepted for presentation at the ESMO Congress 2025 in Berlin. The presentations include a Proffered Paper on the EFTISARC-NEO trial in soft tissue sarcoma, a poster on the INSIGHT-003 trial in non-small cell lung cancer (NSCLC), and an ePoster on the pivotal TACTI-004 Phase ...
07-28 12:00
Integrated Media Technology Appoints New Accounting Firm
Integrated Media Technology ( ($IMTE) ) has provided an announcement. On June 2...
06-26 18:57
Integrated Media Technology Appoints Uwe Henke Von Parpart to Board
Integrated Media Technology ( ($IMTE) ) has issued an update. On June 18, 2025,...
06-18 22:49
Integrated Media Technology Receives Nasdaq Deficiency Notice Over Delayed Annual Report Filing
Integrated Media Technology Limited (NASDAQ:IMTE) ("IMTE" or the "Company"), an Australia company that is engaged in the businesses of the trading in Halal products, the manufacture and sale of nano coated plates for
05-09 00:46
3 Penny Stocks to Watch Now, 25/3/25
Integrated Media Technology, VivoPower International, and MicroCloud Hologram a...
03-25 20:25
